708 623

Cited 0 times in

The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade II Cerebral Gliomas in Adults: Version 2019.01

 Young Zoon Kim  ;  Chae-Yong Kim  ;  Chan Woo Wee  ;  Tae Hoon Roh  ;  Je Beom Hong  ;  Hyuk-Jin Oh  ;  Seok-Gu Kang  ;  Shin-Hyuk Kang  ;  Doo-Sik Kong  ;  Sung Hwan Kim  ;  Se-Hyuk Kim  ;  Se Hoon Kim  ;  Yu Jung Kim  ;  Eui Hyun Kim  ;  In Ah Kim  ;  Ho Sung Kim  ;  Jae-Sung Park  ;  Hyun Jin Park  ;  Sang Woo Song  ;  Kyoung Su Sung  ;  Seung Ho Yang  ;  Wan-Soo Yoon  ;  Hong In Yoon  ;  Jihae Lee  ;  Soon-Tae Lee  ;  Sea-Won Lee  ;  Youn Soo Lee  ;  Jaejoon Lim  ;  Jong Hee Chang  ;  Tae-Young Jung  ;  Hye Lim Jung  ;  Jae Ho Cho  ;  Seung Hong Choi  ;  Hyoung Soo Choi  ;  Do Hoon Lim  ;  Dong-Sup Chung 
 Brain Tumor Research and Treatment, Vol.7(2) : 74-84, 2019 
Journal Title
Brain Tumor Research and Treatment
Issue Date
Grade II Gliomas ; Guideline ; Korean Society for Neuro-Oncology ; Practice

There was no practical guideline for the management of patients with central nervous system tumor in Korea for many years. Thus, the Korean Society for Neuro-Oncology (KSNO), a multidisciplinary academic society, has developed the guideline for glioblastoma. Subsequently, the KSNO guideline for World Health Organization (WHO) grade II cerebral glioma in adults is established.


The Working Group was composed of 35 multidisciplinary medical experts in Korea. References were identified by searching PubMed, MEDLINE, EMBASE, and Cochrane CENTRAL databases using specific and sensitive keywords as well as combinations of keywords regarding diffuse astrocytoma and oligodendroglioma of brain in adults.


Whenever radiological feature suggests lower grade glioma, the maximal safe resection if feasible is recommended globally. After molecular and histological examinations, patients with diffuse astrocytoma, isocitrate dehydrogenase (IDH)-wildtype without molecular feature of glioblastoma should be primarily treated by standard brain radiotherapy and adjuvant temozolomide chemotherapy (Level III) while those with molecular feature of glioblastoma should be treated following the protocol for glioblastomas. In terms of patients with diffuse astrocytoma, IDH-mutant and oligodendroglioma (IDH-mutant and 1p19q codeletion), standard brain radiotherapy and adjuvant PCV (procarbazine+lomustine+vincristine) combination chemotherapy should be considered primarily for the high-risk group while observation with regular follow up should be considered for the low-risk group.


The KSNO's guideline recommends that WHO grade II gliomas should be treated by maximal safe resection, if feasible, followed by radiotherapy and/or chemotherapy according to molecular and histological features of tumors and clinical characteristics of patients.
Files in This Item:
T201905240.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurosurgery (신경외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
Yonsei Authors
Kang, Seok Gu(강석구) ORCID logo https://orcid.org/0000-0001-5676-2037
Kim, Se Hoon(김세훈) ORCID logo https://orcid.org/0000-0001-7516-7372
Kim, Eui Hyun(김의현) ORCID logo https://orcid.org/0000-0002-2523-7122
Yoon, Hong In(윤홍인) ORCID logo https://orcid.org/0000-0002-2106-6856
Chang, Jong Hee(장종희) ORCID logo https://orcid.org/0000-0003-1509-9800
Cho, Jae Ho(조재호) ORCID logo https://orcid.org/0000-0001-9966-5157
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.